The EU Commission accepts a commitment to reduce the price of six cancer medicines by 73% in excessive pricing case in the pharmaceutical industry (Aspen)

On 10 February 2021, the Commission announced that it had accepted a series of pricing and supply commitments from Aspen, thereby bringing an end to its investigation into whether Aspen had infringed Article 102 TFEU by charging excessive prices for six off-patent cancer medicines. Having acquired the cancer medicines from another

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Van Bael & Bellis (Brussels)

Citation

Samuel Hall, The EU Commission accepts a commitment to reduce the price of six cancer medicines by 73% in excessive pricing case in the pharmaceutical industry (Aspen), 10 février 2021, e-Competitions February 2021, Art. N° 99554

Visites 71

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues